Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Home - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 713702 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Printer Friendly
PDF Brochure
Send to Friend
Enquire before Buying
| More
ElectronicAdd to Basket



Stakeholder Insight: Bipolar Disorders - Zyprexa Sets the Mood for Revenue Growth
Datamonitor, Feb 2004, Pages: 250


  Description  
  Table of Contents  
    
    
    
   
 Enquire before Buying  
 Send to a Friend  

Introduction

The bipolar disorder market is experiencing a renewed expansion in product life-cycle management. Presently, mood stabilizers are the basis of treatment, although the antipsychotics led by Zyprexa, are evolving as a new therapeutic strategy. Companies will have to differentiate their products in the increasingly crowded market if they wish to protect their market share.

Scope

Analysis is based on a survey of 164 treating physicians in the seven major markets as well as in-depth interviews with Bipolar key opinion leaders

Detailed treatment trees showing the prevalence, diagnosis and treatment rates of bipolar across the seven major markets

Assessment of the use of mono- and combination-therapy in specific bipolar affective episodes

Identification of therapeutic and diagnostic unmet needs, highlights areas where stakeholder investment is vital to drive patient identification

Report Highlights

Datamonitor primary research has identified variances in class and brand prescribing preferences among physicians, according to BD type and geography; although prescribing trends generally follow recognized national and international guidelines. However, there is concern over the use of tricyclic antidepressants in bipolar depression.

Only 48% of the BD population are accurately diagnosed. Datamonitor has highlighted a number of serious diagnostic issues, which infers that many of the patients currently diagnosed may receive incorrect BD categorization.

Lilly’s Zyprexa is currently leading the bipolar market in terms of revenue and life cycle management, with recent approval for maintenance therapy and reformulation in a combination pill with Prozac as Symbyax. Other atypical antipsychotics appear to be following suit, and could threaten anticonvulsant dominance of mood stabilization.

Reasons to Purchase

Understand differential treatment unmet needs in key patient populations identified by sex, co-morbidities and bipolar disorder type

Gain expert insight into current diagnostic unmet needs and key growth areas in the public and healthcare sectors

Target physicians more effectively, through an understanding of prescribing behavior

Region: US, Japan, France, Germany, Italy, Spain, UK



Top of page


   All rights reserved. � Copyright 2010 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster


Research and Markets RSS Feeds